Bayer’s compulsory licence appeal set to start in India
A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.
The appeal, at the Mumbai High Court, is against a ruling from the Intellectual Property Appellate Board (IPAB) handed down in March this year.
The IPAB upheld a compulsory licence for Bayer’s Nexavar drug, which was issued by the Indian Controller of Patents in 2012.
The licence allowed generic drug company Natco Pharma to manufacture and market cheaper copies of the kidney cancer drug, also known as Sorafenib.
Issuing the licence, the controller said Bayer had not made it publicly available at a reasonably affordable price or sufficiently “worked the patent in India”.
Under the terms of the licence, Natco was ordered to pay Bayer 6 percent royalties on sales of the drug, which the IPAB increased to 7 percent after Bayer's appeal.
But German-based Bayer, having failed in its efforts to overturn the decision, has sought the court's intervention.
Since the decision to issue the compulsory licence, India has since recommended further licenses are issued for Sprycel (dasatinib) and Ixempra (ixabepilone) belonging to Bristol-Myers Squibb and Roche Holding AG’s Herceptin (trastuzumab).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk